GNG5: A Potential Drug Target and Biomarker (G2787)

Target Name: GNG5

NCBI ID: G2787

GNG5

GNG5: A Potential Drug Target and Biomarker

Guanine nucleotide binding proteins (G proteins) are a family of transmembrane proteins that play a crucial role in intracellular signaling. G protein-coupled receptors (GPCRs) are a subfamily of G proteins that are involved in cell signaling, including intracellular signaling, neural signaling, and hormone signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone regulation. GNG5, also known as gamma 5 (纬5), is a GPCR that is involved in intracellular signaling and has been identified as a potential drug target and biomarker.

GNG5 is a 12-kDa protein that is expressed in various tissues, including brain, heart, and kidney. It is a GPCR that is characterized by a extracellular domain that is similar to that of other GPCRs, including G伪, G尾, G纬, and G未. The intracellular region of GNG5 is similar to that of other GPCRs, including G伪1, G尾1, G尾2, G尾3, G尾4, and G尾5.

GNG5 is involved in a wide range of physiological processes, including intracellular signaling, neurotransmission, and hormone regulation. It is involved in the regulation of cell adhesion, migration, and survival. GNG5 has been shown to play a role in the regulation of neural stem cell (NSC) self-renewal and differentiation, as well as in the regulation of neural circuit formation and plasticity.

In addition to its involvement in neural signaling, GNG5 has also been shown to be involved in the regulation of hormone signaling, including the regulation of insulin sensitivity and the regulation of testosterone levels. GNG5 has also been shown to play a role in the regulation of cell signaling pathways, including the regulation of the PI3K/Akt signaling pathway.

GNG5 has been shown to be a potential drug target by various methods, including in vitro and in vivo cell assays, pharmacological and genetic approaches. In vitro assays have shown that GNG5 can be inhibited by small molecules, including inhibitors of G伪 activity and inhibitors of G尾3 activity. In vivo assays have shown that GNG5 can be targeted by small molecules, including inhibitors of GPCR activity and inhibitors of GNG5 expression.

GNG5 has also been shown to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, GNG5 has been shown to be upregulated in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, GNG5 has been shown to be involved in the regulation of cardiovascular diseases, including hypertension and hyperlipidemia.

In conclusion, GNG5 is a GPCR that is involved in intracellular signaling and has been shown to play a role in a wide range of physiological processes, including neural signaling, hormone regulation, and cell signaling pathways. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of GNG5 in various physiological processes and to develop effective strategies for targeting it.

Protein Name: G Protein Subunit Gamma 5

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

The "GNG5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNG5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets